Emgality (galcanezumab) 100 mg strength — United Healthcare

Initial criteria

• Diagnosis of episodic cluster headache
• Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least 3 months
• Medication will not be used in combination with another CGRP antagonist or inhibitor used for preventive treatment of migraines (e.g., Aimovig, Ajovy, Nurtec ODT, Qulipta, Vyepti)

Reauthorization criteria

• Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity
• Medication will not be used in combination with another CGRP antagonist or inhibitor used for preventive treatment of migraines (e.g., Aimovig, Ajovy, Nurtec ODT, Qulipta, Vyepti)

Approval duration

12 months